A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of Iclepertin once daily over 26 week treatment period in patients with schizophrenia (CONNEX-1)

Project: Research

Project Details

StatusActive
Effective start/end date19/05/23 → 19/05/25

Keywords

  • clinical trial
  • Schizophrenia
  • Iclepertin
  • GlyT1 inhibitor